Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

VERONA PHARMA PLC

(VRNA)
  Report
Delayed Nasdaq  -  03:55 2022-11-30 pm EST
13.00 USD   +0.70%
11:17aEuropean Equities Nudge Higher on Slightly Lower Euro Area Inflation
MT
11/28ECB President Lagarde's Comments That Inflation Will Continue to Rise Weigh on European Equities
MT
11/21Rising COVID Cases in China, Plunging Oil Prices Drag European Equities Lower in Monday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Verona Pharma plc Announces Ensifentrine Meets Primary Endpoint in Phase 3 Enhance-2 Trial for COPD

08/09/2022 | 02:00am EST

Verona Pharma plc announced its top-line Phase 3 ENHANCE-2 (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). The ENHANCE-2 trial has successfully met its primary endpoint, as well as secondary endpoints demonstrating improvements in lung function, and significantly reduced the rate and risk of COPD exacerbations. Ensifentrine is a first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3” and “PDE4”) combining bronchodilator and anti-inflammatory activities in one compound.

Study population (n=789): Subject demographics and disease characteristics were well balanced between treatment groups; Approximately 52% of subjects received background COPD therapy, either a long-acting muscarinic antagonist (“LAMA”) or a long-acting beta-agonist (“LABA”). Additionally, approximately 15% of all subjects received inhaled corticosteroids (“ICS”) with concomitant LAMA or LABA. Primary endpoint met (FEV1* AUC 0-12 hr): Placebo corrected, change from baseline in average FEV1 area under the curve 0-12 hours post dose at week 12 was 94 mL (p<0.0001) for ensifentrine; Statistically significant and clinically meaningful improvements with ensifentrine demonstrated across all subgroups including gender, age, smoking status, COPD severity, background medication, ICS use, chronic bronchitis, FEV1 reversibility, and geographic region.

Secondary endpoints of lung function met: Placebo corrected, increase in peak FEV1 of 146 mL (p<0.0001) 0-4 hours post dose at week 12; Placebo corrected, increase in morning trough FEV1 of 49 mL (p=0.0017) at week 12, confirming twice daily dosing regimen. Exacerbation rate reduced: Subjects receiving ensifentrine demonstrated a 42% reduction in the rate of moderate to severe COPD exacerbations over 24 weeks compared to those receiving placebo (p=0.0109); Treatment with ensifentrine significantly decreased the risk of a moderate/severe exacerbation as measured by time to first exacerbation when compared with placebo by 42% (p=0.0088). COPD symptoms and Quality of Life (“QOL”): Daily symptoms and QOL as measured by E-RS Total Score and SGRQ Total Score in the ensifentrine group improved from baseline to greater than the minimal clinically important difference (“MCID”) of -2 units and -4 units, respectively, at week 24.

Improvements in these measures were seen as early as 6 weeks and showed continued improvement at 12 and 24 weeks, numerically exceeding placebo at each measurement. Statistical significance was not achieved due to improvements observed in the placebo group over time. Favorable safety profile: Ensifentrine was well tolerated with safety results similar to placebo, including occurrence of pneumonia, gastrointestinal and cardiovascular adverse events.


ę S&P Capital IQ 2022
All news about VERONA PHARMA PLC
11:17aEuropean Equities Nudge Higher on Slightly Lower Euro Area Inflation
MT
11/28ECB President Lagarde's Comments That Inflation Will Continue to Rise Weigh on European..
MT
11/21Rising COVID Cases in China, Plunging Oil Prices Drag European Equities Lower in Monday..
MT
11/14European ADRs Continue to Trend Higher in Monday Trading
MT
11/10European ADRs Surge Higher as Global Markets React to US Inflation Data
MT
11/10Wedbush Lowers Verona Pharma's Price Target to $23 From $27 Due to Increased Share Coun..
MT
11/09Verona Pharma : VRNA Investor Presentation November 2022
PU
11/09Transcript : Verona Pharma plc, Q3 2022 Earnings Call, Nov 09, 2022
CI
11/09VERONA PHARMA PLC Management's discussion and analysis of financial condition and resu..
AQ
11/09Verona Pharma Swings to Q3 Loss
MT
More news
Analyst Recommendations on VERONA PHARMA PLC
More recommendations
Financials
Sales 2022 6,07 M 7,27 M 7,27 M
Net income 2022 -56,8 M -67,9 M -67,9 M
Net cash 2022 178 M 213 M 213 M
P/E ratio 2022 -22,6x
Yield 2022 -
Capitalization 815 M 976 M 976 M
EV / Sales 2022 105x
EV / Sales 2023 36,0x
Nbr of Employees 25
Free-Float 75,4%
Chart VERONA PHARMA PLC
Duration : Period :
Verona Pharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERONA PHARMA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 12,91 $
Average target price 25,43 $
Spread / Average Target 97,0%
EPS Revisions
Managers and Directors
David S. Zaccardelli President, CEO & Executive Director
Mark W. Hahn Chief Financial Officer
David Raymond Ebsworth Non-Executive Chairman
Kathleen Rickard Chief Medical Officer
Tara Rheault Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
VERONA PHARMA PLC92.11%976
VERTEX PHARMACEUTICALS44.05%81 199
REGENERON PHARMACEUTICALS, INC.17.41%78 615
BIONTECH SE-36.54%39 760
WUXI APPTEC CO., LTD.-34.22%31 776
GENMAB A/S20.91%28 866